Oncodesign, Covalab, CheMatech and ABX-CRO have partnered to launch the DRIVE-MRT (Molecular RadioTherapy) solution. Designed to offer therapeutic development in nuclear medicine, this encompasses theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimisation, preclinical candidate drug generation and IND, to the design and management of clinical trials.
DRIVE-MRT is based on the companies’ joint expertise in nuclear medicine. It covers technologies related to the validation of targets, the generation and optimisation of vectors, the radiochemistry and PET / SPECT imaging techniques, small animal and clinical dosimetry, and a dedicated support for regulatory and clinical studies specific to radiopharmaceuticals.
DRIVE-MRT aims to provide clients with innovative technological platforms and corresponding expertise at each validation step in the development of theranostic drug candidates.
“We can now offer to our pharmaceutical clients a full-continuum, premium radiopharmaceutical drug discovery engine, from preclinic to clinic, together with leading partners”, said Fabrice Viviani, General Manager and Head of the Oncodesign service business unit.
“Covalab is pleased to be a part of this unique DRIVE-MRT project in which we are very keen to bring our know-how and innovative platforms in DNA immunisation, nanobodies, humanisation, etc. This will help in developing innovative molecules for the immunodiagnostic and immunoradiotherapy markets, which are gaining increasing attention from pharmaceutical companies,” said Meddy El Alaoui, CSO at Covalab.
Image credit: Oncodesign
